Browsing Tag
Nasdaq INTS
1 post
Breakthrough results: Intensity Therapeutics’ INT230-6 delivers strong survival and immune response in phase 1/2 cancer trial
Find out how Intensity Therapeutics’ INT230-6 achieved 11.9-month survival and immune activation in metastatic cancer—read what this means for biotech investors.